BioBlast® - Search
FDA approves use of ustekinumab in children with psoriatic arthritis
Janssen announced that the FDA has approved Stelara® (ustekinumab) for the treatment of paediatric patients aged six and over with active psoriatic arthritis (PsA). As there were insufficient paediatric patients with PsA to conduct clinical trials, the FDA based its approval on phase III trials in adults and children with plaque psoriasis and adults with PsA.
PBAC considers 5 biosimilar applications
Janssen’s Stelara® (ustekinumab): requesting a General Schedule Authority Required listing of a new form for the treatment of patients with Crohn disease and chronic plaque psoriasis
Formycon publishes Q1/22 financial results
Formycon published its Q1 2022 financial results, reporting sales and other earnings of EUR 8.2 million. Formycon also announced the addition of two biosimilar projects to its pipeline, FYB208 and FYB209, for undisclosed products. Late stage Formycon development programs include biosimilars to Lucentis® (ranibizumab), Stelara® (ustekinumab) and Eylea® (aflibercept). Formycon plans to launch its biosimilar to Lucentis® (ranibizumab) in the second half of 2022.
Alvotech announces study results for AVT04, biosimilar ustekinumab
Alvotech announced positive top-line results from a 3 arm, parallel design study conducted in Australia and New Zealand regarding AVT04 (ustekinumab biosimilar), reporting that the study results demonstrate bioequivalence between AVT04 and Janssen’s Stelara®. Teva and Stada are Alvotech’s exclusive strategic partners for commercialising AVT04 in the US and EU respectively.
Merck to present data on six medicines at ASCO 2022
Merck announced that it will present data from studies of six medicines and pipeline candidates in more than 25 cancers at the 2022 American Society of Clinical Oncology Annual Meeting in June. This will include data on Keytruda® (ustekinumab), Lenvima® (lenvatinib) and its investigational anti-LAG-3 therapy favezelimab.
Formycon and Athos announce closing of acquisition
Formycon and Athos KG announced closing of the acquisition by Formycon of 100% of the rights to FYB201 (biosimilar ranibizumab), a 50% of the rights to FYB202 (biosimilar ustekinumab), together with Bioeq GMBH, which is described as its “long-time partner”. The total value of the deal is €650M.
Amgen releases preliminary results from its Ph III study of ABP654 (proposed ustekinumab biosimilar)
Amgen released preliminary results from its Ph III study of ABP654 (proposed ustekinumab biosimilar) in adults with severe plaque psoriasis. Amgen reported that the study met the primary efficacy endpoint, and that the safety profile of ABP654 was comparable to STELARA®.
Formycon and Athos KG announce long-term strategic partnership for biosimilars
Formycon and Athos KG announced that they have agreed to enter into a long-term strategic partnership regarding biosimilars. As part of this agreement, Formycon will acquire 100% of the rights in FYB202 (biosimilar ustekinumab candidate) and a 50% stake in FYB201 (biosimilar ranibizumab candidate) in exchange for EUR 650 million.
Remdesivir replaces Humira® as the most expensive drug by total member spend in Vizient’s Winter 2022 Market Outlook
Vizient announced that remdesivir has replaced Humira® (adalimumab) as the most expensive drug by total member spend in its Winter 2022 Market Outlook. Pembrolizumab, ustekinumab, ocrelizumab, denosumab, infliximab, nivolumab and tocilizumab also featured in the top 10 most expensive drugs by member spend.
Hyphens Pharma and Favorex Pte Ltd announce commercialisation deal for Alvotech’s proposed ustekinumab biosimilar
Hyphens Pharma announced that it has signed an exclusive license and supply agreement with DKSH’s subsidiary Favorex Pte Ltd for the commercialisation of Alvotech’s proposed biosimilar ustekinumab in Singapore, Malaysia and the Philippines.
Alvotech and Oaktree Acquisition Corp. II announce merger agreement
Alvotech and Oaktree Acquisition Corp. II announced that they have entered into a merger agreement for the creation of a publicly-traded global biopharmaceutical company. Alvotech is led by a team of highly experienced biopharma leaders, including Mark Levick as CEO, Anil Okay as CCO, and Philip Caramanica as Chief IP Counsel and Deputy General Counsel. The merger is expected to deliver gross proceeds to Alvotech in excess of USD$450 million. Alvotech currently has seven products in its pipeline, including a biosimilar candidate to Humira® (adalimumab), Stelara® (ustekinumab), Eylea® (aflibercept), Prolia®/Xgeva® (denosumab) and Simponi®/Simponi ARIA® (golimumab).
Celltrion provides update on biosimilars pipeline
Celltrion announced its Q3 2021 financial results. Celltrion reported that Remsima® (infliximab biosimilar) has obtained a 53% market share in Europe and 21% market share in Japan. Celltrion reported that Truxima® (rituximab biosimilar) has obtained a 40% market share in Europe and Herzuma® (trastuzumab biosimilar) has obtained a 14% market share in Europe. Celltrion also reported that it expects to launch biosimilar bevacizumab in 2022, biosimilar ustekinumab in 2023, biosimilar omalizumab and aflibercept in 2024 and biosimilar denosumab in 2025.
Janssen announced data from two new analyses of the use of Stelara® (ustekinumab) in Crohn’s disease and ulcerative colitis
Janssen announced data from two new analyses of Stelara® (ustekinumab) for the treatment of adults with Crohn’s disease and ulcerative colitis. Janssen reported that the data from these analyses provides additional support for Stelara® as a first-line option for Crohn’s disease and ulcerative colitis.
Bio-Thera Solutions and Pharmapark reach deal for ustekinumab biosimilar
Bio-Thera Solutions announced it has reached a licensing and supply agreement with Pharmapark for BAT2206 (proposed ustekinumab biosimilar). Under the agreement, Pharmapark will have exclusive rights to distribute and market the product in Russia and other CIS countries.
Janssen submits sBLA for Stelara® (ustekinumab
Janssen announced the submission of a sBLA to the FDA seeking expanded approval of Stelara® (ustekinumab) to treat paediatric patients aged 5 years and older with juvenile psoriatic arthritis.
BioFactura and Rani Therapeutics enter into agreement relating to proposed ustekinumab biosimilar
BioFactura announced it has reached an agreement with Rani Therapeutics to assess BFI-751 (proposed ustekinumab biosimilar) in combination with the RaniPill® platform. The RaniPill® capsule is intended to replace subcutaneous or IV injection of biologics with oral dosing.
Bio-Thera and Hikma sign commercialisation agreement for ustekinumab biosimilar
Bio-Thera Solutions and Hikma Pharmaceuticals announced that they have signed an exclusive commercialisation and license agreement for BAT2206 (proposed ustekinumab biosimilar). Under the agreement, Hikma will gain exclusive commercialisation rights in the US with a first-right-to-negotiate to add Europe (excluding CIS countries) to the agreement.
Intas Pharma and Meiji and Dong-A St sign commercialisation agreement for ustekinumab biosimilar
Intas Pharma announced it has signed a commercialisation agreement with Meiji and Dong-A St for DMB-3115 (proposed ustekinumab biosimilar). Under the agreement, Intas will receive exclusive licensing rights to DMB-3115 worldwide excluding Japan, Korea and certain countries in Asia.
Samsung Bioepis commences Ph III ustekinumab trials
Samsung Bioepis announced that it has commenced Ph III trials of SB17 (proposed ustekinumab biosimilar) in patients with moderate to severe plaque psoriasis.
Bio-Thera Solutions doses first patient in ustekinumab trials
Bio-Thera Solutions announced that the first patient has been dosed in its Ph III trials of BAT206 (proposed ustekinumab biosimilar).
AU’s PBAC recommends listing Mvasi, Keytruda and Stelara
Australia’s PBAC recommended the listing of Amgen’s Mvasi® (biosimilar bevacizumab). The PBAC also recommended listing Keytruda® (pembrolizumab) for the first line treatment of unresectable or metastatic mismatch repair deficient colorectal cancer and recommended listing Stelara® (ustekinumab) for the treatment of paediatric patients with severe chronic plaque psoriasis.
Alvotech doses first patient in AVT04 (proposed ustekinumab) trials
Alvotech announced that the first patient has been dosed in the comparative, confirmatory efficacy and safety clinical study for AVT04 (proposed ustekinumab biosimilar). The trial is being conducted in Central and Eastern Europe and approximately 530 patients are expected to be enrolled in the study.
BioFactura initiates Ph I trials of ustekinumab biosimilar
BioFactura announced the initiation of Ph I trials of BFI-751 (proposed ustekinumab biosimilar). The trial is being conducted across three sites in Australia and New Zealand.
Meiji Seika Pharma releases results of Ph I trials of ustekinumab biosimilar
Meiji Seika Pharma announced its Ph I trials of DMB-3115 (proposed ustekinumab) biosimilar demonstrated the bioequivalence of its product to the reference product.
Celltrion reports Q1 2021 financial results
Celltrion released its Q1 2020 financial results, reporting that YoY sales of Celltrion biosimilars increased by 23%. Celltrion announced that it is planning to complete Ph III trials of biosimilar bevacizumab in the first half of 2021, and that ustekinumab, aflibercept, omalizumab and denosumab candidates remain in Ph III trials.
AU | NZ |
Cipla expands biosimilar partnership with Alvotech for ANZ
Cipla and Alvotech announced that they have expanded their partnership for the marketing and distribution of four biosimilar medicines in Australia and New Zealand. The agreement includes biosimilar aflibercept, ustekinumab, denosumab and golimumab candidates. This agreement is in addition to the previous agreement between Alvotech and Cipla for the commercialisation of AVT02 (biosimilar adalimumab candidate).
Vizient releases Pharmacy Market Outlook
Health care performance improvement company Vizient releases its Winter 2021 Pharmacy Market Outlook. Vizient projected that the greatest price increases to members would occur in Humira® (adalimumab), with a 7.5% price increase predicted over the next 18 months. Adalimumab also topped the list of greatest total spend by product among Vizient members, followed by pembrolizumab, rituximab, infliximab, ustekinumab, nivolumab and denosumab. New figures also showed trastuzumab biosimilars have captured a significant market share, contributing to 39% of cost to members in September 2020.
Celltrion provides ustekinumab update
Celltrion announces Ph III trials of its proposed ustekinumab biosimilar CT-P43 will be completed by the second half of 2022. Celltrion also announced plans to launch the product when the API patents expire in the EU in September 2023 and in the US in July 2024.
Formycon and Bioeq commence Ph III trials of ustekinumab
Formycon and Bioeq announce they have commenced dosing in Ph III trials of FYB202 (proposed ustekinumab biosimilar) in patients with moderate to severe plaque psoriasis.
Amgen releases Q3 2020 financial results
In its Q3 2020 financial results, Amgen announces that it is moving ABP 654 (proposed ustekinumab biosimilar) into Ph III development.
Ph III clinical trials of FYB202 commence
Ph III clinical trials of FYB202 (proposed ustekinumab biosimilar developed by Formycon and Bioeq) commence recruiting in Poland.
NeuClone announces Ph I clinical trials ustekinumab biosimilar results
NeuClone announces its proposed ustekinumab biosimilar has successfully met all primary and secondary endpoints in Ph I clinical trials. Noelle Sundstrom, CEO of NeuClone announced that the company plans to enter Ph III trials in 2021. The product is being jointly developed by NeuClone and the Serum Institute of India.
Polpharma publishes ustekinumab biosimilar is under development
Polpharma publishes ustekinumab biosimilar is under development.
Congress of Clinical Rheumatology East presents results from new study on ustekinumab
A new study presented at the Congress of Clinical Rheumatology East indicates that ustekinumab is safe and efficacious in young and elderly patients with psoriatic arthritis. Researchers reported that there were no clinically meaningful differences in the effectiveness and safety in PsA patients 60 years or older compared with those younger than 60.
Bio-Thera Solutions commences clinical trials of BAT2206
Bio-Thera Solutions commences dosing in Ph I clinical trials of BAT2206 (proposed ustekinumab biosimilar).
FDA approves additional indication for Janssen Stelara®
Janssen announces the FDA approved an additional indication for Stelara® (ustekinumab) for paediatric patients with skin lesions or moderate to severe plaque psoriasis.
Humira® sales negatively impacted by prescription of alternative mechanism of action agents
Spherix reports that the EU market for AbbVie’s Humira® has been negatively impacted by gastroenterologists increasingly prescribing alternative mechanism of action agents, including Stelara® (ustekinumab) and Entyvio® (vedolizumab) for ulcerative colitis (UC) and Crohn’s disease (CD) and the increased prescription of adalimumab biosimilars. These increases have come at a cost to AbbVie, with use of Humira® in UC and CD decreasing in the EU.
Janssen discontinues Ph III LOTUS study of Stelara®
Janssen announces it has discontinued its Ph III LOTUS study of Stelara® (ustekinumab) in Systematic Lupus Erythematosus due to lack of efficacy.
Formycon update on biosimilar portfolio
Formycon releases an update on its biosimilar portfolio. Ph III clinical trials for a proposed ustekinumab biosimilar are scheduled to commence in Q3 2020.
NeuClone Pharma announces progress for Ph I trials of NeuLara
NeuClone Pharma announces it has completed monitoring visits and blood sampling for Ph I trials of NeuLara.
Janssen announces additional indication for Stelara® approved
Janssen announces approval of additional indication of ulcerative colitis for Stelara® (ustekinumab) in Japan.
J&J announces Dano® indication
J&J announces Dano® is now also indicated for the treatment of adults with moderate to severe Crohn’s Disease.
Health Canada approves additional indication for Stelara®
Health Canada approves ulcerative colitis as an additional indication for Stelara®.
UK’s NICE discourages Stelara®
The UK’s NICE announces it will not recommend Stelara® for moderately to severely active ulcerative colitis due to uncertainties over cost-effectiveness.
NeuClone announces completion of patient recruitment and dosing in Ph I trials of biosimilar ustekinumab
NeuClone announces completion of patient recruitment and dosing in Ph I trials of ustekinumab biosimilar.
Dong-A Socio Holdings and Meiji Seika announce commencement of Ph I trials of biosimilar ustekinumab
Dong-A Socio Holdings and Meiji Seika announce commencement of Ph I trials of ustekinumab biosimilar.
Bio-Thera announces NMPA approval to commence Ph I trials of biosimilar ustekinumab
Bio-Thera announces NMPA approval to commence Ph I trials of ustekinumab biosimilar.
Formycon announced dosing has begun in Ph I trials of biosimilar ustekinumab
Formycon announces dosing has begun in PhI clinical trials of ustekinumab biosimilar.
NeuClone announces commenced dosing in Ph I trials of biosimilar ustekinumab
NeuClone announces it has commenced dosing in Phase I clinical trials of biosimilar ustekinumab candidate.
Janssen announces EC approval for additional indication for Stelara®
Janssen announces EC approval for additional indication for Stelara®. Stelara® is now indicated for the treatment of ulcerative colitis.
JHL Biotech publishes ustekinumab biosimilar is under development
NeuClone confirms Ph I trials of biosimilar ustekinumab
NeuClone confirms Ph1 trials of biosimilar ustekinumab will commence in the second half of 2019, as previously announced.
Alvotech and Fuji Pharma announce exclusive agreement for commercialisation of Stelara®biosimilar in Japan
Alvotech and Fuji Pharma announce exclusive agreement for the commercialisation of Stelara® biosimilar in Japan. Alvotech will be responsible for development and supply while Fuji Pharma will receive exclusive rights to commercialise the drug in Japan. This follows Fuji Pharma’s recent US $50 million investment in Alvotech.
NeuClone announces preclinical results for biosimilar ustekinumab
Australia’s NeuClone announces preclinical results for its biosimilar ustekinumab, which are now scheduled for Ph 1 clinical trials in 2019.
NeuClone confirms ongoing development of biosimilar ustekinumab
Australia’s NeuClone confirms ongoing development of biosimilar ustekinumab, which is on target to enter Ph I trials in 2018. Read more
Formycon is developing biosimilar ustekinumab
Germany’s Formycon is developing biosimilar ustekinumab, targeting 2023 for a US launch, and 2024 for EU launch. Read more
Product specific reports based on extracts from our BioBlast® database
BioBlast® Editor and Contributing Author
Get our Pearce IP Blogs & BioBlast® sent directly to your inbox
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.